© 2021 MJH Life Sciences and Urology Times. All rights reserved.
© 2021 MJH Life Sciences™ and Urology Times. All rights reserved.
June 09, 2021
Data presented during the 2021 ASCO Annual meeting showed that fewer patients in the lenvatinib/everolimus arm were treated with subsequent anticancer treatments compared with patients in the sunitinib arm.
“Recurrence of urothelial cancer, in particular metastatic recurrence, is associated with a detriment in quality of life in this exploratory analysis,” says Matthew Galsky, MD.
June 08, 2021
Nizar M. Tannir, MD, discusses results from the phase 2 CANTATA study of cabozantinib plus telaglenastat in patients with advanced/metastatic renal cell carcinoma.
The study explored pembrolizumab versus placebo following nephrectomy in patients with clear cell renal cell carcinoma.
The phase 2 HCRN GU16-257 trial explored the bladder-sparing regimen of TURBT plus nivolumab and chemotherapy in patients with muscle-invasive bladder cancer.
June 07, 2021
A 1-year bladder-intact disease-free survival rate of 89% was observed across the entire phase 2 study cohort.
The health-related quality of life data come from the phase 3 CLEAR trial. The FDA is currently reviewing efficacy data from this trial supporting an application for pembrolizumab plus lenvatinib in frontline renal cell carcinoma.
“It could be that the integration of a new treatment modality into the bladder-sparing arena is a tipping point that is needed to really have the community embrace this as a reasonable option for patients with bladder cancer,” says Matthew Galsky, MD.
The final KEYNOTE-426 analysis represents the longest follow-up of a checkpoint inhibitor plus a VEGF/VEGFR inhibitor in frontline clear cell RCC, according to the investigators.
June 06, 2021
Robert J. Motzer, MD, discusses how the outcomes of the phase 3 CLEAR trial impact the use of pembrolizumab/lenvatinib in patients with renal cell carcinoma.